Search research articles
Contact Us
Filters
Showing results (51-60 of 88) with videos related to
Page
of 9
Sort By:
Gut
|
August 4, 2019
Adeno-associated virus in the liver: natural history and consequences in tumour development
Tiziana La Bella, Sandrine Imbeaud, Camille Peneau, et al.
Neurology
|
October 19, 2022
Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort
Vincent Planche, Vincent Bouteloup, Isabelle Pellegrin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 19, 2025
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies
Jennifer G Goldman, Bradley F Boeve, Douglas Galasko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 4, 2019
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A Labeur, Sarah Berhane, Julien Edeline, et al.
Lancet (London, England)
|
February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Journal of Alzheimer'S Disease : JAD
|
March 18, 2017
Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort
Milica G Kramberger, Bjørn Auestad, Sara Garcia-Ptacek, et al.
Neurology
|
January 28, 2026
Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories
Rakesh Kumar, Stephanie Gravett, Vesna Jelic, et al.
JAMA
|
July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial
Andrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
BMJ Open
|
June 2, 2019
What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
Emmanuel Cognat, François Mouton Liger, Anne-Cécile Troussière, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 88) with videos related to
Sort By:
Page
of 9
Gut
|
August 4, 2019
Adeno-associated virus in the liver: natural history and consequences in tumour development
Tiziana La Bella, Sandrine Imbeaud, Camille Peneau, et al.
Neurology
|
October 19, 2022
Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort
Vincent Planche, Vincent Bouteloup, Isabelle Pellegrin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 19, 2025
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies
Jennifer G Goldman, Bradley F Boeve, Douglas Galasko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 4, 2019
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A Labeur, Sarah Berhane, Julien Edeline, et al.
Lancet (London, England)
|
February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Journal of Alzheimer'S Disease : JAD
|
March 18, 2017
Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort
Milica G Kramberger, Bjørn Auestad, Sara Garcia-Ptacek, et al.
Neurology
|
January 28, 2026
Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories
Rakesh Kumar, Stephanie Gravett, Vesna Jelic, et al.
JAMA
|
July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial
Andrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
BMJ Open
|
June 2, 2019
What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
Emmanuel Cognat, François Mouton Liger, Anne-Cécile Troussière, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
Page
of 9